Gilead gets into in vivo Car-T
Interius, one of the most advanced players, will cost $350m.
Better late than never for Datroway in lung cancer
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Lyell takes on J&J and Gilead
The players are vying in the CD19 x CD20 Car-T arena.
ASCO 2025 – Trodelvy heads for the front line
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Galapagos split stutters
The group’s point-of-care Car-T push looks to have stalled.
